SCHEMBL30765628

SCHEMBL30765628

C[C@@H](Nc1cnc(-c2ccccc2F)n(CC(=O)O)c1=O)c1ccc(-c2ccccc2F)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 1/20 0.43
ELANE P08246 7/20 0.41
GRIA4 P48058 4/20 0.39
CTSA P10619 3/20 0.38
BRS3 P32247 1/20 0.38
KDM4E B2RXH2 1/20 0.38
ASPH Q12797 1/20 0.38
RIOX2 Q8IUF8 1/20 0.38
KDM8 Q8N371 1/20 0.38
BDKRB1 P46663 1/20 0.37
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
ATP1A1 P05023 1/20 0.37
ATP1B1 P05026 1/20 0.37
ATP1A3 P13637 1/20 0.37
ATP1B2 P14415 1/20 0.37
ATP1A2 P50993 1/20 0.37
ATP1B3 P54709 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765563 0.87 PDE2A (0.40) PDE2AELANEGRIA4KDM4EBDKRB1
SCHEMBL30765929 0.85 L3MBTL1 (0.44) PDE2AELANEGRIA4
SCHEMBL30766151 0.83 ELANE (0.37) ELANECTSA
SCHEMBL30765981 0.83 LMNA (0.37) ELANECTSAKDM4EASPHRIOX2
SCHEMBL31558470 0.83 LMNA (0.37) ELANECTSAKDM4EASPHRIOX2
SCHEMBL30765747 0.82 ELANE (0.39) ELANECTSAKDM4E
SCHEMBL31558417 0.82 PDE2A (0.41) PDE2AGRIA4CTSABRS3BDKRB1
SCHEMBL31558558 0.82 PDE2A (0.41) PDE2AGRIA4CTSABRS3BDKRB1
SCHEMBL30765454 0.81 ELANE (0.37) ELANECTSA
SCHEMBL31558547 0.79 PDE2A (0.41) PDE2AELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed